Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1996 2
1999 2
2000 4
2001 2
2002 3
2003 3
2004 8
2005 1
2006 4
2007 6
2008 4
2009 4
2010 3
2011 12
2012 7
2013 16
2014 13
2015 17
2016 12
2017 8
2018 11
2019 9
2020 18
2021 15
2022 16
2023 14
2024 14
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Results by year

Filters applied: . Clear all
Page 1
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P. Hiemke C, et al. Among authors: conca a. Pharmacopsychiatry. 2018 Jan;51(1-02):9-62. doi: 10.1055/s-0043-116492. Epub 2017 Sep 14. Pharmacopsychiatry. 2018. PMID: 28910830 Free article. Review.
Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study).
Martinotti G, Vita A, Fagiolini A, Maina G, Bertolino A, Dell'Osso B, Siracusano A, Clerici M, Bellomo A, Sani G, d'Andrea G, Chiaie RD, Conca A, Barlati S, Di Lorenzo G, De Fazio P, De Filippis S, Nicolò G, Rosso G, Valchera A, Nucifora D, Di Mauro S, Bassetti R, Martiadis V, Olivola M, Belletti S, Andriola I, Di Nicola M, Pettorruso M, McIntyre RS, di Giannantonio M; REAL-ESK Study Group. Martinotti G, et al. Among authors: conca a. J Affect Disord. 2022 Dec 15;319:646-654. doi: 10.1016/j.jad.2022.09.043. Epub 2022 Sep 24. J Affect Disord. 2022. PMID: 36167246
Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie.
Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, Robinson DG, Goff DC, Kelly DL, Freudenreich O, Piacentino D, Paulzen M, Conca A, Zernig G, Haen E, Baumann P, Hiemke C, Gründer G; American Society of Clinical Psychopharmacology; Pharmakopsychiatrie TTDMTFOTAFNU. Schoretsanitis G, et al. Among authors: conca a. J Clin Psychiatry. 2020 May 19;81(3):19cs13169. doi: 10.4088/JCP.19cs13169. J Clin Psychiatry. 2020. PMID: 32433836 Free article.
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P. Hiemke C, et al. Among authors: conca a. Pharmacopsychiatry. 2018 Jan;51(1-02):e1. doi: 10.1055/s-0037-1600991. Epub 2018 Feb 1. Pharmacopsychiatry. 2018. PMID: 29390205 No abstract available.
Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics.
Hart XM, Gründer G, Ansermot N, Conca A, Corruble E, Crettol S, Cumming P, Frajerman A, Hefner G, Howes O, Jukic MM, Kim E, Kim S, Maniscalco I, Moriguchi S, Müller DJ, Nakajima S, Osugo M, Paulzen M, Ruhe HG, Scherf-Clavel M, Schoretsanitis G, Serretti A, Spina E, Spigset O, Steimer W, Süzen SH, Uchida H, Unterecker S, Vandenberghe F, Verstuyft C, Zernig G, Hiemke C, Eap CB. Hart XM, et al. Among authors: conca a. World J Biol Psychiatry. 2024 Nov;25(9):451-536. doi: 10.1080/15622975.2024.2366235. Epub 2024 Sep 1. World J Biol Psychiatry. 2024. PMID: 38913780 Review.
Suicide risk in attention-deficit/hyperactivity disorder.
Giupponi G, Giordano G, Maniscalco I, Erbuto D, Berardelli I, Conca A, Lester D, Girardi P, Pompili M. Giupponi G, et al. Among authors: conca a. Psychiatr Danub. 2018 Mar;30(1):2-10. doi: 10.24869/psyd.2018.2. Psychiatr Danub. 2018. PMID: 29546852 Free article. Review.
Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis.
Hart XM, Hiemke C, Eichentopf L, Lense XM, Clement HW, Conca A, Faltraco F, Florio V, Grüner J, Havemann-Reinecke U, Molden E, Paulzen M, Schoretsanitis G, Riemer TG, Gründer G. Hart XM, et al. Among authors: conca a. Psychopharmacology (Berl). 2022 Nov;239(11):3377-3391. doi: 10.1007/s00213-022-06233-2. Epub 2022 Oct 5. Psychopharmacology (Berl). 2022. PMID: 36195732 Free PMC article.
208 results